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~ Exocrine pancreatic function and resting energy expenditure in 
Cystic Fibrosis 
T. Moudiou, A. Galli-Tsinopoulou, S. Nousia-Arvanitakis. 4th Department of 
Pediatrics, Aristotle Universily, Thessaloniki, Greece 
The aim of this study was to prove the hypothesis that exocrine pancreatic function 
determines resting energy expenditure (REE) in Cystic Fibrosis (CF). 
Thirty-eight CF individuals (9 to 34, 19.98±1.0 yrs) were divided in two groups: 
32 patients, who had exocrine pancreatic nsufficiency (PI) (Group A) and 6 patients 
with pancreatic sufficiency (PS) (Group B). A sub-group C included 19 PI patients 
whose predicted FEV1% was comparable to that of Group B. Indirect calorimetry 
and Schofield equations were applied to calculate predicted REE. Measured REE 
was expressed as % of the predicted values. BMI and BMI z-scores were related 
to REE. 
The results were expressed as mean±standard error. Group A had increased 
REE% (113±3.81%) as opposed to group B whose REE% was similar to the 
predicted values (98.9±3.81%) (p 0.022). Sub-group C also had increased REE% 
(110.82±2.72%), which was comparable to that of group A and significantly 
different from group B (p 0.035). Mean FEV1% was 74.53±4.9%, 86.33±10.1% 
92.1±4.55%, mean BMI was 19.7±0.5, 25.6±2.06 and 19.13±0.66 and BMI 
z-scores were 0.72±0.2, 0.75±0.51 and 0.62±0.26, in Group A, B and C, 
respectively. Significant correlation was demonstrated between REE% and BMI 
z-scores in-group B (r 0.83, p 0.038) but not in groups A and C. 
Conclusions: Clinically stable CF patients with similar pulmonary function ex- 
hibited increased REE% only in the presence of exocrine pancreatic insufficiency. 
Pancreatic sufficiency was related to normal REE%. Furthermore, REE% strongly 
correlated with BMI z-scores in pancreatic sufficiency but not in pancreatic 
insufficiency. These findings support he hypothesis that exocrine pancreatic rather 
than pulmonary function may determine nutritional status and REE% in CF patients. 
6. Gastroenterology 
1~ Treatment with ALTU-135 results in a positive inverse relationship 
between coefficient of fat absorption with stool weight in 
subjects with Cystic Fibrosis-related pancreatic insufficiency 
D. Borowitz 1, M.W Konstan 2, C. Goss 3'4, S.E. Limauro 5, F.T. Murray 5, 
S. Casey 3, ALTU-135 Study Group 6. 1SUNY, Buffalo, NY; 2Rainbow Babies' 
and Children~' Hospital, Cleveland, OH; 3TDN, Seattle, WA; 4University of 
Washington, Seattle, WA; 5Altus Pharmaceuticals' Inc., Cambridge, MA, USA; 
6 USA 
Pancreatic insufficiency (PI) occurs in 89% of patients with cystic fibrosis (CF) and 
current herapy includes formulations derived from crude porcine extract. ALTU- 
135 is a microbially derived enzyme therapy incorporating novel cross-linking 
and protein crystallization technology to create highly purified, stable and potent 
enzymes. 
Methods: Subjects (n 125) were screened and randomized to one of three 
treatment arms of ALTU- 135 for four weeks; Dose: Lipase/Prote ase/Amylase (Units 
USP/meal or snack): Arm 1: 5,000/5,000/750; Arm 2: 25,000/25,000/3,750; Arm 3: 
100,000/100,000/15,000. During the treatment period, subjects were provided a 
controlled iet (100g of fat/day) for 72h, beginning and ending with a highly 
visible blue dye marker. Novel methodology using dye marker ensured a complete 
stool collection for determination f stool weight and coefficient of fat absorption 
(CFA). 
Results: There was a significant difference between baseline and treatment stool 
weight (p ~< 0.0001) for all treatment groups. All treatment arms alone and in com- 
bination exhibited a significant inverse correlation between baseline stool weight 
and baseline CFA (r 0.7551; p<0.0001) and a significant inverse correlation 
between treatment s ool weight and treatment CFA (r 0.7517; p < 0.0001). There 
was also high correlation between the change in stool weight with the change in 
CFA (r 0.7283; p < 0.0001). 
Conclusions: ALTU-135 significantly decreases stool weight while improving CFA 
in patients with CF-related PI. 
I •  Exocrine pancreatic function evaluation in patients with 
Cystic Fibrosis and pancreatic sufficiency: a correlation study 
M. Wilschanski 1 , A. Weintraub 1 , H. Mussaffi 2, H. Blau 2, E. Picard 3, L. Bentur 4, 
E. Kerem 1 . 1 Cystic Fibrosis' Cente~ Hadassah University HosTital, .Jerusalem; 
2 CF Cente~ Schneider Childrens Hospital, Petach Tiqvah; 3 CF Cente~ Shaare 
Zedek Medical Cente~ Jerusalem; 4 CF Center, Rambam Hospital Hails, Israel 
Background: Most patients with Cystic Fibrosis have pancreatic nsufficiency (PI), 
however, 15% of the patients are pancreatic sufficient (PS). Many laboratory tests 
have been developed in order to examine xocrine pancreatic function to distinguish 
between PI and PS. The 'gold-standard' to determine pancreatic function apart from 
direct pancreatic stimulation test is the fecal fat excretion during 72 h, expressed as 
coeffiecient of fat absorption (CFA). Other tests include fecal elastase and serum 
immuno-reactive trypsinogen (IRT).Aim: To test the correlation between elastase 
and IRT as compared to fecal fat excretion, thereby, to evaluate the best available 
test to determine xocrine pancreatic function in CF patients. 
Methods: 21 CF PS patients performed the 3 tests of fecal fat excretion, elastase 
and IRT. Correlation between the tests was evaluated by the kappa statistics test, 
sensitivity, specificity, positive and negative predictive values. 
Results: The correlation between CFA and IRT was negative (kappa 0.154), and 
between CFA and elastase was poor (kappa 0.213). The sensitivity, specificity, 
positive and negative predictive values of IRT vs. CFA were: 0%, 88%, 0%, and 
78%, respectively, and for elastase were: 40%, 81%, 40%, and 81% respectively. 
Conclusion: Poor correlation was found between IRT, elastase and CFA, therefore, 
neither elastase in the stool nor IRT in the serum has the sensitivity or the specificity 
to replace the 'gold standard' test of fecal fat excretion during 72 h. Thus, despite 
the technical difficulties and the inconvenient of collecting stool, there is a need to 
evaluate precisely the pancreatic function of the CF patients, at least at the time 
of diagnosis, and non-infrequently during the follow-up period, especially when 
changes in clinical parameters occur. 
1• Enhanced coefficient of fat absorption using a novel pancreatic 
enzyme preparation, ALTU-135, with concomitant use of a 
proton pump inhibitor 
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Background: A randomized ouble-blind parallel dose study of subjects (n 125) 
with CF-related PI was conducted with a novel acid-stable microbially-derived 
pancreatic enzyme replacement therapy (ALTU-135) to determine the most effective 
dose to increase oral fat absorption on and off acid suppression. 
Methods: Subjects were randomized to one of three treatment arms: Li- 
pase/Protease/Amylase (Units USP/meal or snack) 
Arm 1:5,000/5,000/750 
Arm 2:25,000/25,000/3,750 
Arm 3:100,000/100,000/15,000 
Subjects were stratified based on acid suppression use. Analysis of variance tested 
for differences in the treatment arm means for coefficient of fat absorption (CFA). 
Pairwise comparisons among treatment arms utilized Tukey's tudentized range test. 
Results: Proton pump inhibitors (PPIs) were associated with increased CFA 
response to ALTU-135 (p 0.0062). No significant increases were observed in 
subjects receiving H2 receptor antagonists or antacids. Mean increases in CFA 
were higher for subjects on PPI versus subjects oil': 10.0% v. 3.4%, 17.7% v. 
8.4%, and 23.2% v 15.1% for Arms 1, 2, and 3 respectively. This difference is 
significant at the lowest dose (p 0.007) and approaches significance with Arms 2 
and 3 combined (p 0.058). 
Conclusions: An acidic intestinal environment contributes to fat malabsorption by 
causing bile salt precipitation, which results in reduced lipid solubilization and 
lipolysis. Given the consistent activity of crystalline bacterial lipase in ALTU-135 
across a wide range ofpH,  we believe that the use of a PPI improves the treatment 
effect of ALTU-135 by preventing bile salt precipitation. 
